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ABSTRACT
Signaling through immune checkpoint receptors may lead to T-cell exhaustion 
and function as immune escape mechanisms in cancer. For diffuse large B-cell 
lymphoma (DLBCL), the mechanistic and prognostic importance of these markers on 
tumor cells and the tumor microenvironment remains unclear. 
We determined the immunohistochemical expression of PD-1, PD-L1, TIM-3, and 
LAG-3 on tumor cells and on tumor infiltrating lymphocytes (TILs) among 123 DLBCL 
patients. TIM-3 showed positive staining on tumor cells in 39% of DLBCL cases and 
PD-L1 expression was noted in 15% of cases. Both PD-1 and LAG-3 were positive on 
tumor cells in a minority of DLBCL cases (8.3% and 7.5%, respectively), but were 
more widely expressed on TILs in a correlated manner. With median follow-up of 
44 months (n = 70, range 5–85), 4-year progression-free survival (PFS) and overall 
survival (OS) rates were significantly inferior among DLBCL patients with high vs low/
negative TIM-3 expression (PFS: 23% [95% CI 7% to 46%] vs 60% [95% CI 43% 
to 74%], respectively, P = 0.008; OS: 30% [95% CI 10% to 53%] vs 74% [95% CI 
58% to 85%], respectively, P = 0.006). Differences in OS remained significant when 
controlling for International Prognostic Index in Cox regression analyses (HR 3.49 
[95% CI 1.40–6.15], P = 0.007). In addition, we observed that co-culture of DLBCL 
cell lines with primed T cells in the presence of anti-LAG-3 and anti-TIM-3 induced 
potent dose-dependent increases in in vitro cell death via AcellaTox and IL-2 ELISA 
assays, suggesting potent anti-tumor activity of these compounds. 
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INTRODUCTION
Significant advances have been made in the use 
of immuno-modulating therapies in the treatment of a 
range of human malignancies, most notably inhibitors of 
programmed cell death-1 (PD-1) in relapsed and refractory 
Hodgkin lymphoma (HL) [1, 2]. A number of hematologic 
malignancies, including HL and diffuse large-B cell 
lymphoma (DLBCL), express the PD-1 ligands, PD-L1 
and PD-L2, presumably as a means of dysregulating the 
immune response through PD-1:PD-L1/L2 interactions 
between tumor cells and T lymphocytes leading to T-cell 
exhaustion [3–5]. Immunotherapeutic targeting of tumor 
cells in vitro with humanized antibodies to PD-1 or PD-
L1 disrupt this interaction, thus restoring the anti-tumor 
activity of the T cells, forming the basis for this approach 
to immunotherapy [4]. Overexpression of PD-L1/L2 
in lymphoma has been shown to occur through various 
mechanisms, including activation of JAK/STAT pathways, 
EBV-driven mechanisms, and 9p24.1 gene amplifications 
[6–8]. Expression of PD-L1 by DLBCL has been linked to 
inferior outcome, demonstrating the potential importance 
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for both prognostic and treatment selection [9, 10]. Tumor 
infiltrating lymphocytes (TILs) in lymphoma have also 
been shown to frequently express the immune checkpoint 
molecule PD-1 [11, 12].
Two additional immune checkpoint molecules 
investigated in the context of cancer immunotherapy 
include TIM-3 (T cell immunoglobulin and mucin 
domain-containing protein-3) and LAG-3 (lymphocyte 
activation gene-3, CD223) [13, 14]. TIM-3 is a type I 
transmembrane protein expressed on several types of 
immune cells, most notably on CD4+ Th1 and CD8+ 
cytotoxic T cells, that functions to limit the duration and 
magnitude of T-cell responses [13, 15]. In the setting of 
human cancers, TIM-3 is expressed on the T cells found in 
a range of malignancies, including melanoma, lung cancer, 
hepatocellular, and colon cancer. In these tumors, TIM-
3 expression is often associated with dysfunctional T-cell 
function, as well as poorer prognosis in some tumor types 
(reviewed in [13]). In hematologic malignancies, TIM-3 
expression has been observed in adult T-cell leukemia/
lymphoma and extranodal NK/T cell lymphoma [16, 17]. 
TIM-3 was also found to be increased in peripheral blood 
CD3+ T cells of patients with DLBCL, which was related 
to tumor stage and response to conventional chemotherapy 
[18, 19].
LAG-3 is a member of the immunoglobulin 
superfamily and functions as a negative regulator of 
T-cell homeostasis. Upregulated LAG-3 expression 
was originally discovered in activated CD4+, CD8+ and 
NK cell subsets [20]. LAG-3 binds to MHC class II at a 
higher affinity relative to CD4, while LAG-3 expressed 
in cytotoxic T and NK cells binds to LSECtin commonly 
expressed in various tumors, as well as normal hepatocytes 
[14]. LAG-3 has been shown to be expressed in TILs 
of several tumor types, including breast, ovarian, and 
lung cancers, often in connection with increased PD-1+ 
T cells [21–23]. In syngeneic mouse tumor models of 
fibrosarcoma or adenocarcinoma, a combination of anti-
PD-1 and anti-LAG-3 antibodies had a synergistic effect 
on tumor growth inhibition. LAG3-/-/PDCD1-/- double 
knockout mice have also shown enhanced clearance of 
and survival from multiple transplanted tumor types [24]. 
LAG-3 has been shown to be expressed by intratumoral 
T cells in cases of HL, particularly in areas rich in the 
malignant Reed-Sternberg cells [25]. In follicular 
lymphoma, a subset of intratumoral PD-1+ T cells 
were also found to be LAG-3+, which correlated with 
functionally exhausted T cells and inferior outcome [26]. 
Given the functions of TIM-3 and LAG-3 in 
controlling T-cell activation, these molecules are under 
consideration as alternate pathways for the regulation of 
tumor-induced immune evasion that could be blocked to 
promote T-cell mediated anti-tumor immunity. However, 
there remains a considerable lack of data related to LAG-3 
or TIM-3 expression in DLBCL, as well as other tumors, 
despite a number of clinical trials for anti-LAG-3 or anti-
TIM-3 therapies (as single agent or combinations) in solid 
tumors and hematologic malignancies. In the current 
analyses, we characterized the immunohistochemical 
expression of PD-1, PD-L1, LAG-3 and TIM-3 in tumor 
cells and TILs in a cohort of untreated DLBCL patients 
and correlated their expression with pathologic and 
clinical features. In addition, we evaluated the effects of 
investigational anti-PD-1, anti-LAG-3 and anti-TIM-3 
antibodies in in vitro cytotoxic assays of tumor-primed T 
cells against DLBCL cell lines. 
RESULTS
Expression of immune checkpoint receptors in 
DLBCL
Tissue sections (whole sections and TMA) of 
newly diagnosed cases of DLBCL (n = 123) as described 
were examined for PD-1, PD-L1, TIM-3, and LAG-3 
expression by immunohistochemistry. Representative 
photomicrographs of cases stained by IHC are shown in 
Figure 1. Staining results are summarized in Table 1. TIM-
3 showed strong, membranous staining (TIM-3 score ≥80) 
on tumor cells in 39% of DLBCL cases (48/123). PD-L1 
was expressed (≥30% tumor cells positive) in 15.6% of 
DLBCL (19/122), similar to previously published data 
from our group as well as others [9, 10]. There was a 
positive trend between TIM-3 and PD-L1 expression on 
tumor cells, but this was not statistically significant. 
Both PD-1 and LAG-3 were positive on tumor cells 
in only a minority of DLBCL samples (8.3% and 7.5%, 
respectively). Conversely, PD-1 and LAG-3 were widely 
expressed on TILs found in DLBCL in 77% and 84.7% of 
cases, respectively. For PD-1, the range of TILs per HPF 
was 0-250 with a median number of 15 and average of 
31.8 positive lymphocytes/HPF. For LAG-3, the range of 
TILs per HPF was 0-200 with a median number of 40 and 
average of 46.1 positive lymphocytes/HPF. There was a 
positive correlation between counts for PD1+ TILs and 
counts for LAG3+ TILs (r = 0.32, p < 0.001). Counts for 
LAG3+ TILs also positively correlated with counts for 
TIM3+ TILs (r = 0.29, p < 0.001). TIM-3 status on tumor 
cells did not appear to correlate with PD1+ TIL or LAG3+ 
TIL counts. 
TIM-3 association with survival 
Clinicopathologic features, treatment, and outcome 
data were available for 70 patients (Table 2). The majority 
of patients received R-CHOP therapy (64%). With median 
follow-up of 44 months (range 5–85), the median PFS 
for all patients was 24 months, and the median OS for 
all patients was 29 months. Furthermore, the 4-year PFS 
and OS rates were significantly inferior among DLBCL 
patients with high (TIM-3 score ≥80) vs low/negative 
TIM-3 expression (PFS: 23% (95% CI 7% to 46%) vs 
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60% (95% CI 43% to 74%), P = 0.008; OS: 30% (95% CI 
10% to 53%) vs 74% (95% CI 58% to 85%), P = 0.006) 
(Figure 2). When controlling for International Prognostic 
Index, the difference in PFS lost statistical significance 
(P = 0.10) while the difference in OS maintained statistical 
significance (HR 3.49, 95% CI 1.40–6.15, P = 0.007) in 
Cox regression analyses. 
Cell mediated cytotoxicity with anti-TIM-3 or 
anti-LAG-3 
Considering that we observed PD-1, TIM-3 and 
LAG-3 expression in TILs, and TIM-3 expression in tumor 
cells of many cases of DLBCL, we next investigated 
the effects of blocking PD-1, TIM-3 and LAG-3 in the 
Figure 1: Representative images of immunohistochemistry in DLBCL. (A) High PD-1 expression in lymphoma cells. (B) 
Negative PD-1 expression in tumor cells, positive in TILs. (C) High PD-L1 expression in lymphoma cells. (D) Negative PD-L1 expression 
in tumor cells, positive in TILs. (E) High TIM-3 expression in lymphoma cells. (F) Negative TIM-3 expression in tumor cells, positive in 
TILs. (G) High LAG-3 expression in lymphoma cells. (H) Negative LAG-3 expression in tumor cells, positive in TILs.
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context of tumor-specific cytotoxic activity. For these 
experiments, we utilized isogenic CD8+ T cells and 
DCs to prepare tumor-specific cytotoxic T cells via DC-
mediated priming as detailed in the Methods. Following 3 
weeks of differentiation and maturation of DCs, and DC-
mediated priming of T cells with irradiated lymphoma 
cell lines (Raji or SUDHL-10), the isolated T cells were 
investigated for cytotoxic activity against actively growing 
Raji or SUDHL-10 tumor cells, in the presence or absence 
of anti-PD-1, anti-TIM-3, or anti-LAG-3 experimental 
compounds. For these experiments, T cells were derived 
from 2 separate donors and used in similar sequential 
experiments. 
Results from our experiments with initial tumor-
primed CD8+ T cells against Raji cells showed that 
anti-LAG-3, but not anti-TIM-3, induced a potent dose-
dependent increase in cell-mediated cytotoxicity with 
15 nM IC50 compared to 61.25 nM IC50 using unprimed/
resting T cells, as determined by AcellaTox-Glo assay 
(Figure 3A, 3B). However, we observed a dose-dependent 
Table 1: IHC analysis of DLBCL cases
Marker %
PD-L1 (n = 122) Tumor positive cases 15.6
TIL/TAM positive cases 36.1
TIM-3 (n = 123) Tumor positive cases 39.0
TIL positive cases 76.2
PD-1 (n = 120) Tumor positive cases 8.3
TIL positive cases 77.0
Avg positive TILs/HPF 31.8
LAG-3 (n = 120) Tumor positive cases 7.5
TIL positive cases 84.7
Avg positive TILs/HPF 46.1
Abbreviations: PD-L1, programmed cell death ligand-1; TIM-3, T cell immunoglobulin and mucin domain-containing 
protein-3; PD-1, programmed cell death-1; LAG-3, lymphocyte activation gene-3, CD223; TIL, tumor infiltrating 
lymphocytes; TAM, tumor associated macrophages; HPF, high power field; Avg, average.
Table 2: Clinicopathologic characteristics of DLBCL patients
Characteristic All patients TIM3 low TIM3 high P
Gender (n) Male 32 24 8
0.20*
Female 38 23 15
Median Age (yrs) 69 70 68 0.47#
Performance Status (n) 0–1 35 24 11
0.08*
2+ 17 11 6
NA 18
Stage (n) 1-2 28 21 7
0.22*
3-4 38 23 15
NA 4
IPI Score (n) 0-2 33 26 7
0.02*
3+ 24 12 12
NA 13
Treatment (n) R-CHOP 45 31 14
0.68*
Other 25 16 9
*Chi-square test.
#t-test.
Abbreviations: TIM-3, T cell immunoglobulin and mucin domain-containing protein-3; n, number; yrs, years; GCB, 
germinal center; NA, not available; IPI, International Prognostic Index; R-CHOP, rituximab, cyclophosphamide, 
doxorubicin, oncovin, prednisone.
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increase in IL-2 release from both primed and resting T 
cells with the addition of anti-LAG-3 in the presence of 
Raji cells, but not with anti-TIM-3 (data not shown), based 
on IL-2 ELISA assay (Figure 3C). 
Using tumor-primed CD8+ T cells derived from a 
second donor and primed with either irradiated SUDHL10 
or Raji cells, primed T cells showed increased TIM-3 and 
PD-1 expression compared to resting/unprimed CD8+ 
T cells, as determined by flow cytometry (Figure 3D), 
suggesting activation of immune checkpoints in these T 
cells. We then performed the AcellaTox cell-mediated 
cytotoxicity assay with anti-TIM-3, anti-LAG-3, anti-
PD-1 and control IgG using these T cells. With anti-
TIM-3, we observed a potent dose-dependent increase in 
the cytotoxicity of SUDHL10-primed compared to Raji-
primed T cells against Raji cells (Figure 3E, 3F), despite 
both sets of tumor-primed T cells being TIM-3+ by flow 
cytometry (Figure 3D). With anti-LAG-3, a statistically 
significant difference in GAPDH release compared 
with control was observed at the highest concentration 
Figure 2: Kaplan–Meier survival. High TIM-3 expression on DLBCL tumor cells correlates with inferior progression-free survival 
(PFS) with 4-year PFS 23% vs 60%, respectively, P = 0.008 and overall survival (OS) with 4-year OS 30% vs 74%, respectively, P = 0.006.
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(>200nM) with SUDHL10-primed T cells, but not with 
Raji-primed T cells (Figure 3E, 3F). Additionally, there 
was no detectable presence of LAG3 by flow cytometry 
(data not shown), highlighting the variability between T 
cells primed with different antigens. 
DISCUSSION
DLBCL is an aggressive and heterogeneous non-
Hodgkin lymphoma (NHL) that has been shown to respond 
in limited circumstances to anti-PD-1 monotherapy, while 
responses are more robust in HL. Checkpoint blockade for 
NHL, in general, has not shown consistent results, except 
in cases with genetically defined 9p24.1 amplification, 
such as primary mediastinal B-cell lymphoma [27], for 
which pembrolizumab was recently approved by the US 
FDA for treatment of patients with relapsed/refractory 
disease [28]. There remains much more limited data 
regarding the checkpoint molecules TIM-3 and LAG-3 
in DLBCL. Overall, the heterogeneity of the expression 
Figure 3: Co-culture of DLBCL and primed T cells. Matured and differentiated isogenic dendritic cells (DC) were used to prime 
T cells derived from donor#1 using irradiated Raji cells for two weeks, with IL-2 supplementation. Primed T cells, unprimed T cells, at 
4:1 ratio (T cells:Raji) were co-cultured with target cells for 4 hours ((A, B) for Acellatox GAPDH release assay) or 72 hours ((C) for IL-2 
release assay). Matured and differentiated isogenic dendritic cells (DC) were used to prime T cells derived from donor#2 using irradiated 
SUDHL10 or Raji cells for two weeks, and isolated primed T cells were analyzed for PD-1 and TIM-3 expression by flow cytometry (D), 
or co-cultured with target cells at 4:1 ratio for 4 hours ((E) SUDHL10 or (F) Raji cells), and assayed for cell mediated cytotoxicity using 
Acellatox GAPDH release assay. (**denotes P < 0.05, ***denotes P < 0.001, compared with isotype IgG).
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of checkpoint molecules on DLBCL tumor cells and 
the microenvironment needs further study to determine 
mechanistic and prognostic features important for patient 
outcome, as well as to identify new immune targets for 
treatment. The goal of this study was to investigate the 
expression pattern of PD-1, PD-L1, TIM-3 and LAG-3 in 
DLBCL. 
We demonstrate for the first time that TIM-3 is 
highly expressed in DLBCL tumor cells in over a third 
of cases (39%), as well as in TILs. We also found a 
correlation between high TIM-3 expression and worse 
overall survival in univariate analysis that persisted when 
controlling for IPI score. These data suggest that the tumor 
microenvironment in DLBCL is likely directly affected 
by TIM-3 expression by tumor cells and TILs leading 
to decreased immune surveillance and tumor clearance. 
This is analogous to the immunosuppressive concept 
of PD-L1 and PD-1 expression in tumors, particularly 
where PD-L1 expression in DLBCL was also correlated 
with worse overall survival [9, 10]. We found a trend in 
positive correlation between TIM-3 and PD-L1 expression 
on tumor cells that was not statistically significant in 
this cohort. Larger studies will be necessary to better 
understand the relationships between checkpoint molecule 
expression. The precise mechanisms of TIM-3 expression 
in DLBCL lymphoma cells, and the consequences of 
tumor versus TIL expression of TIM-3, are of interest to 
further understanding the importance of TIM-3 expression 
in lymphoma. 
For PD-1 and LAG-3, we did not find a large 
number of cases with tumor cells expressing these 
markers; although a significant minority of cases with 
positive tumor expression showed strong expression. 
Interestingly, we found that almost all cases of DLBCL 
contained TILs that express PD-1 and LAG-3 in a 
correlated manner. Expression of these markers on TILs 
did not appear to correlate with patient outcome, nor 
did they appear to correlate with the expression patterns 
of PD-L1 or TIM-3 on tumor cells. The possibility, 
however, that expression of PD-1 and LAG-3 on TILs, as 
well as on tumor cells in a minority of cases, represents 
an indicator of immune dysregulation is certainly of 
interest. In future experiments, multicolor analysis and 
flow cytometry approaches will help further elucidate 
immune signatures that could further predict response (or 
resistance) to combination immunotherapy and prognosis. 
Co-expression of PD-1 and LAG-3 observed in exhausted 
TILs present in follicular lymphoma were found to be 
responsive to combined blockade of both PD-1 and LAG-3 
[26]. Prior studies based on retrospective analysis reported 
a correlation between elevated expression of PD-1 and 
TIM-3 in CD3+ T cells with a poor response to standard 
chemotherapy in newly diagnosed DLBCL patients [18]. 
It was also reported that PD-1, TIM-3 and LAG-3 are 
elevated in a subset of BTLA+ T cells and correlated with 
poor prognosis in DLBCL [29]. These studies highlight the 
potential interplay among multiple checkpoint molecules 
in the pathogenesis of lymphoma. 
In the in vitro studies, we demonstrated blocking 
activity by anti-TIM-3 and anti-LAG-3 compounds in 
our experimental model system consisting of tumor-
primed cytotoxic CD8+ T cells. We found that the effect 
of the compounds was variable between the different 
batches of donor-derived T cells, lymphoma cells used 
for priming, and target lymphoma cell lines. While these 
data provide initial evidence that blockade of TIM-3 or 
LAG-3 may induce T cell anti-lymphoma activity, further 
comprehensive analysis of these effects are needed to fully 
define the biological activity and potential utility of these 
compounds to target DLBCL utilizing isogenic cytotoxic 
CD8+ T cells and tumor cells derived from lymphoma 
patients. Furthermore, patient-specific characteristics 
will be essential to identifying and developing optimal, 
personalized therapies. 
MATERIALS AND METHODS
Patients
Patient cases of untreated DLBCL diagnosed 
between 2000 and 2014 were retrieved from the surgical 
pathology files and medical records. The study was 
approved by all Institutional Review Boards. All cases 
were diagnosed and classified according to 2008 World 
Health Organization criteria. One-hundred and twenty-
three cases of patients with untreated DLBCL were 
identified, a subset of which were reported in a prior study 
[10]. Thirty-seven DLBCL cases were part of a tissue 
microarray (TMA), and 86 cases DLBCL were studied as 
whole sections. A subset of TMA cases were also studied 
as whole sections with similar results (data not shown). 
Original diagnostic pathology reports were examined for 
pathologic features including germinal center (GC) vs 
non-GC characterization.
Patient demographics, clinical data, treatment and 
outcome information were available among 70 untreated 
DLBCL cases. Clinical parameters included gender, 
age, stage, performance status, lactate dehydrogenase 
(LDH), bone marrow involvement, other extranodal 
sites involvement, International Prognostic Index (IPI), 
treatment history, the dates of disease progression, relapse 
or death and cause of death.
Immunohistochemistry and evaluation
Immunohistochemistry using anti-PD-L1 (clone 
E1L3N, #13684, Cell Signaling Technologies (CST), 
Danvers, MA, USA), anti-PD-1 (clone EH33, #43248, 
CST), anti-TIM-3 (clone D5D5R, #45208, CST), and anti-
LAG-3 (clone 17B4, #40466, Abcam, Cambridge, MA, 
USA) antibodies was performed on 5 μm-thick, formalin-
fixed paraffin embedded (FFPE) tissue sections and TMA 
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sections using a Dako Autostainer (Dako Corporation, 
Carpinteria, CA, USA) with antigen retrieval methods 
(0.01 M citrate buffer at pH 6.0) as described previously 
[10]. The UltraView Universal DAB Detection kit (#760-
500, Ventana Medical Systems, Tuscon, AZ, USA) 
was used according to the manufacturer instructions. 
Counterstaining was done as part of the automated 
staining protocol using hematoxylin (#760-2021, Ventana 
Medical Systems). 
All IHC-stained sections were evaluated and scored 
by two hematopathologists independently. Discrepancies 
in scoring (<10% of cases) were resolved by consensus 
conference between the two pathologists. For tumor cell 
staining (as identified by morphologic examination), 
intensity of PD-L1, PD-1, TIM-3, and LAG-3 was scored 
as follows: 0 (no staining), 1+ (weak), 2+ (moderate), 
or 3+ (strong). The percentage of tumor cells showing 
any positivity was recorded. For PD-L1, tumors were 
considered positive if ≥30% of tumor cells exhibited 
2–3+ staining, as defined previously. [10] PD-L1+ non-
malignant cells (TILs and tumor associated macrophages 
[TAM]) as a percentage of total tumor cellularity was also 
recorded [6, 10]. For PD-1 and LAG-3, ≥1+ intensity 
in ≥10% tumor cells was considered positive. Tumor 
infiltrating lymphocytes (TILs) that were positive for 
PD-1 or LAG-3 were enumerated by recording the average 
number of positive lymphocytes from 2-3 40x fields in 
an area of highest density. For TIM-3, multiplying the 
staining intensity by percent tumor cells staining positive 
produced a TIM-3 score ranging from 0-300. A TIM-3 
score of =/>80 was considered positive. Positive controls 
including placenta for PD-L1 and tonsil sections for PD-
1, TIM-3, and LAG-3 were included in each batch of IHC 
staining. 
Statistical analysis
Characteristics were compared using t-test for 
continuous variables for means, chi-square test for 
categorical variable distributions, or Wilcoxon rank-sum 
for medians. Covariates were collected and comprised 
the data set on which univariate analyses for PFS and 
OS were performed. PFS was calculated from the date of 
diagnosis to date of death or disease relapse/progression. 
OS was computed from the date of diagnosis to the 
date of death. Patients without PFS or OS events were 
censored at the time of last clinical follow-up. Survival 
analyses were performed regardless of amount or length 
of therapy received. Four-year PFS and OS rates were 
estimated through Kaplan-Meier method, while survival 
differences were assessed using the log-rank test. 
Multivariate associations between clinical and laboratory 
factors and survivals (PFS or OS) were derived using 
parametric survival modeling with Weibell distribution. 
Hazard ratios (HRs) and their 95% confidence intervals 
(CI) were reported. All statistical analyses were conducted 
with STATA v13 (StrataCorp LP, College Station, Texas). 
Statistical correlation between IHC results were determined 
using Pearson’s method with correlation coefficient r 
> 0.25 and P < 0.001 at 95% CI reported in the analysis 
conducted with Originlab (Northampton, MA, USA).
Generation of tumor-specific cytotoxic T cells
Isogenic CD8+ T and monocytes, negatively 
isolated from two separate donors were purchased from 
Astarte Biologics, Bothell, WA, USA. To generate DCs, 
0.5 × 106 monocytes were cultured using ImmunoCult 
Dendritic Cell Culture Kit (Stemcell Technologies, 
Vancouver, Canada) in 24 well plates for 2 days, followed 
by medium supplementation with differentiation cocktail 
and incubation for 2 days, then a maturation cocktail 
supplied in the kit, following instructions provided by 
the manufacturer. Tumor priming was performed using 
irradiated lymphoma tumor cells (SUDHL10, derived 
from a germinal center DLBCL; or Raji, derived from a 
Burkitt lymphoma) prepared by exposing the tumor cells 
to 30 Gy γ-radiation using Cs-137 Shepherd irradiator 
(Tufts University) and culturing for an additional 6 
hours. On day 7, 2.5 × 105 DCs were co-cultured with 
irradiated tumor cells at a 1:1 ratio and maintained for 
16 hours, followed by supplementation with maturation 
cocktail for an additional 24 hours. For T-cell stimulation, 
antigen-pulsed adherent DCs were rinsed with medium to 
remove irradiated tumor cell suspension and co-cultured 
with T cells at a 1:10 ratio in LGM-3 medium (Lonza, 
Walkersville, MD, USA) containing 5% human serum 
and IL-2 (10 U/ml). IL-2 was supplemented on days 12, 
15 and 19, followed by harvesting T cells to perform cell 
mediated cytotoxicity assay on day 20.
Cell-mediated cytotoxicity assay
T-cell mediated cytotoxicity was performed by 
using AcellaTox-Glo based GAPDH release assay, as per 
manufacturer provided instructions (Cell Technology Inc. 
Freemont, CA, USA). Briefly, 0.5X104 SUDHL-10 or 
Raji cells were used as target cells with tumor-specific 
cytotoxic T cells as effector cells at a 1:5 ratio. T cells 
were pre-incubated with indicated concentrations of 
antibodies, cell culture supernatant was collected after 5 
hours of co-culture and assayed as previously described 
[30].  
IL-2 ELISA
Briefly, 0.5 × 104 SUDHL-10 or Raji cells were 
used as target cells with tumor specific cytotoxic T cells 
as effector cells at a 1:5 ratio. T cells were pre-incubated 
with indicated concentrations of antibodies, cell culture 
supernatant was collected after 24 hours of incubation and 
assayed for IL-2 release using Human IL-2 DuoSet ELISA 
(R&D Biosystems, Minneapolis, MN, USA) following 
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manufacturer provided instructions. Anti-PD-1, anti-
TIM-3, anti-LAG-3 compounds for in vitro assays were 
generously provided by Tesaro.
Flow cytometry
PD-1 (D3W4U), TIM-3 (D5D5R), isotype rabbit 
IgG and anti-rabbit IgG (H+L) fragment Alexa Fluor 
488 were purchased from Cell Signaling Technologies. 
1 × 106 cells were washed twice in ice-cold stain buffer 
(BD Bioscience, San Jose, CA, USA), centrifuged at 300 
g at 4° C, and re-suspended in 100 mL of stain buffer 
and incubated for 20 minutes on ice with appropriate 
dilutions of antibody. Stained cells were washed twice 
and re-suspended in 500 mL of stain buffer and analyzed 
immediately using CyAn ADP flow cytometer with 
Summit software (Beckman Coulter, Pasadena, CA, USA).
CONCLUSIONS
In conclusion, the IHC expression of the immune 
molecules PD-1, PD-L1, TIM-3, and LAG-3 were 
associated with heterogeneous profiles in DLBCL. High 
TIM-3 expression in tumor cells, found in over a third of 
DLBCL cases, was associated with inferior PFS and OS. 
Furthermore, by using tumor-primed cytotoxic T cells 
and anti-TIM-3 and anti-LAG-3 compounds in in vitro 
experiments, we found evidence of increased anti-tumor 
activity against DLBCL cell lines following checkpoint 
blockade. Altogether, these findings support the need 
for continued characterization of tumor immune profiles 
and delineation of the mechanistic basis for checkpoint 
inhibitors in DLBCL. 
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